

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rolf EHRHARDT, *et al.*

Appl. No. Not Yet Assigned

Filed: Herewith

For: **ANIMAL MODEL FOR PSORIASIS
FOR THE PREVENTION AND
TREATMENT OF PSORIASIS IN
HUMANS**

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Atty. Docket: 05882.0003.PCUS00

Information Disclosure StatementCommissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited

by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required, or
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and
 - ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
 - ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
 - ☐ c. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i), and

- ☐ a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- ☐ b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 4. Relevance of the non-English language document(s) is discussed in the present specification.
- ☐ 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- ☐ 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- ☐ 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.
- ☐ 8. Copies of the documents were cited by or submitted to the Office in Application No. _____, filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

531 Rec'd PC


07 JUN 2001

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 05882.0003.PCUS00.

Respectfully submitted,

Date: June 7, 2001


Albert P. Halluin (Reg. No. 25,227)
Viola T. Kung (Reg. No. 41,131)

HOWREY SIMON ARNOLD & WHITE, LLP

301 Ravenswood Avenue
Box No. 34
Menlo Park, CA 94025
(650) 463-8109

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

541 HOD PC..

07 JUN 2001

05882.0003.PCUS00

Not Yet Assigned

APPLICANT

Rolf EHRHARDT, et al.

FILING DATE

Herewith

GROUP

Not Yet Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.	5,780,597	07/14/98	Gately, et al.	530	388.23	06/02/95
	2.	5,945,576	08/31/99	Christina M. Parker	800	9	04/05/96
	3.	09/457,912		Ehrhardt, et al.			12/08/99

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

	4.	Boehncke, et al., "Pulling the trigger on psoriasis," <i>Nature</i> , 379:777 (1996)
	5.	Chang, Jennie C. C., et al., "CD8+T Cells in Psoriatic Lesions Preferentially Use T-Cell Receptor Vt, 3 and/o: Vs13.1 Genes," <i>Proc. Natl. Acad. Sci. USA</i> (Sept. 1994) Vol. 91: 9282-9286. '
	6.	Menssen, Antje, et al., "Evidence for an Antigen-Specific Cellular Immune Response in Skin Lesions of Patients with Psoriasis Vulgaris," <i>Journal of Immunology</i> , 155:4078-4083 (1995)
	7.	Nickoloff, Brian J., et al., "Animal Model of Psoriasis," <i>Nature Medicine</i> , 3(5): 475-476 (1997)
	8.	Neurath, et al., "Antibodies to interleukin 12 abrogate established experimental colitis in mice," <i>J. Exp. Med.</i> , 182:1281-1290 (1995)
	9.	Schon, Michael P., et al., "Animal models of psoriasis. What can we learn from them?," <i>J. Invest. Dermatol.</i> , 112:405-410 (1999)
	10.	Schon, Michael P., et al., "Murine Psoriasis-Like Disorder Induced by Naive CD4+T Cells," <i>Nature Medicine</i> , 3(2):183-187 (1997)
	11.	Smith-Wrone Tamara, et al., "Dermal Injection of Immunocytes Induces Psoriasis," <i>J. Clin. Invest.</i> , 98(8):1878-1887 (1996).
	12.	Sugai, Junichi, et al., "Histological and Immunocytochemical Studies of Human Psoriatic Lesions Transplanted Onto SCID Mice, n <i>Journal of Dermatological Science</i> , 17:85-92 (1998)
	13.	Tsuji, Jumio, et al., "Involvement of Leukotriene B4 in Murine Dermatitis Models," <i>Biochemical Pharmacology</i> , 55:297-304 (1998)
	14.	Yawalker, et al., "Expression of Interleukin-12 is increased in psoriatic skin," <i>J. Invest. Dermatol.</i> , 111:1053-1057 (1998)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.